{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:17:50Z","timestamp":1777493870078,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To describe the longer-term effectiveness, safety, and tolerability of open-label ziprasidone in children and adolescents with bipolar I disorder (BD-I).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A subset of 23 participants aged 10\u201317 years, who were previously treated in a multi-site, 4-week randomized controlled trial received open-label ziprasidone (20\u201380 mg twice a day) for up to 26 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The most common adverse events (AEs) were fatigue (30%), somnolence (17%), and nausea (13%). Effects on weight, body mass index, and metabolic parameters (glucose, cholesterol, and triglycerides) were minimal. No participant had a Fridericia-corrected QT interval \u2265\u2009460 msec or a change from baseline of \u226560 msec, and there were no cardiac-related AEs. Both the participants who continued ziprasidone and those who initiated ziprasidone in the open-label extension showed improvements in their symptoms of mania.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      The overall findings of the study are consistent with the accumulating knowledge on the safety profile of ziprasidone in the acute and long-term treatment of children and adolescents with BD-I, in the midst of a manic episode.\n                      <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrial.gov\">ClinicalTrial.gov<\/jats:uri>\n                      ID: NCT03768726.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2022.0030","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T13:08:25Z","timestamp":1666703305000},"page":"453-458","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic)"],"prefix":"10.1177","volume":"32","author":[{"given":"Sarah","family":"Atkinson","sequence":"first","affiliation":[{"name":"Psychiatry, Child and Adolescent Psychiatry, Finger Lakes Clinical Research, Rochester, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Bachinsky","sequence":"additional","affiliation":[{"name":"Clinical Development and Operations, Pfizer, Inc., Groton, Connecticut, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaron","family":"Raiter","sequence":"additional","affiliation":[{"name":"Clinical Development, GE Healthcare, Eindhoven, The Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Abreu","sequence":"additional","affiliation":[{"name":"Global Biometrics and Data Management, Pfizer, Inc., New York, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Ianos","sequence":"additional","affiliation":[{"name":"Worldwide Medical and Safety, Pfizer AG, Zurich, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-6236","authenticated-orcid":false,"given":"Phillip","family":"Chappell","sequence":"additional","affiliation":[{"name":"Clinical Development and Operations, Pfizer, Inc., Groton, Connecticut, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Findling","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2010.09.011"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200210000-00011"},{"key":"e_1_3_5_5_1","first-page":"922","article-title":"A 52-week study of olanzapine with a randomized behavioral weight counseling intervention in adolescents with schizophrenia or bipolar 1 disorder","volume":"26","author":"Detke HC","year":"2016","unstructured":"Detke HC, , Delbello MP, , Landry J, , Hoffman VP, , Heinloth A, , Dittmann RW: A 52-week study of olanzapine with a randomized behavioral weight counseling intervention in adolescents with schizophrenia or bipolar 1 disorder. JCAP, 26:922\u2013934, 2016.","journal-title":"JCAP"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2021.0121"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2012.0029"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2012.0092"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-016-0184-2"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/eb-2018-102912"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07104"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0717"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/10401239509149039"},{"key":"e_1_3_5_14_1","doi-asserted-by":"crossref","unstructured":"Guy W (eds): ECDEU Assessment Manual for Psychopharmacology\u2014Revised. Maryland Rockville Md publications 1976.","DOI":"10.1037\/e591322011-001"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.741"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2008.11.004"},{"key":"e_1_3_5_17_1","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review","volume":"28","author":"Peuskens J","year":"2014","unstructured":"Peuskens J, , Pani L, , Detraux J, , De Hert M: The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review. CNS Drugs, 28:421\u2013453, 2014.","journal-title":"CNS Drugs"},{"key":"e_1_3_5_18_1","unstructured":"Posner K Brent D Lucas C Gould M Stanley B Brown G Fisher P Zelazny J Burke A Oquendo M Mann J (eds): Coloumbia Suicide Severity Rating Scale Version 7\/19\/2008. New York Psychiatric Institute 2008."},{"key":"e_1_3_5_19_1","first-page":"979","article-title":"Children's Depression Rating Scale Revised","volume":"21","author":"Poznanski EO","year":"1985","unstructured":"Poznanski EO, , Freemen LN, , Mokros HB: Children's Depression Rating Scale Revised. Psychopharmacol Bull, 21:979\u2013989, 1985.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_5_20_1","unstructured":"Poznanski EO Mokros HB: Children's Depression Rating Scale Revised Manual. LA Western Psychological Services 1996."},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790100074010"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0569-y"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2017.08.002"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1637416"},{"key":"e_1_3_5_26_1","unstructured":"Zeldox SmPC. (Summary of Product Characterstics). 2019. https:\/\/docetp.mpa.se\/LMF\/Zeldox%20capsule %20hard%20ENG%20SmPC_09001be68001708b.pdf Accessed October8 2022."}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2022.0030","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2022.0030","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2022.0030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:56:29Z","timestamp":1777388189000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2022.0030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1089\/cap.2022.0030"],"URL":"https:\/\/doi.org\/10.1089\/cap.2022.0030","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}